Trial Profile
A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2020
Price :
$35
*
At a glance
- Drugs Dalcetrapib (Primary)
- Indications Atherosclerosis; Coronary disorders
- Focus Therapeutic Use
- Acronyms dal-PLAQUE
- Sponsors Roche
- 09 Sep 2011 Results published in the Lancet.
- 31 Aug 2011 Results presented at the ESC Congress 2011: Annual Congress of the European Society of Cardiology.
- 29 Aug 2011 Results were presented at the European Society of Cardiology Congress, according to a Roche media release.